|
⚲
|
| Trails Edge Capital Partners LP
✚
|
|
|---|---|
| CRD # | 335659 |
| SEC # | 801-132963 |
| CIK # | 0002077247 |
| AUM | $933.4 M (2026-04-14) |
| Employees | 7 (71% Investors, 0% Brokers) |
| Phone | 770-600-9010 |
| Address | 3445 Peachtree Road NE Atlanta, GA 30326 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Vaxcyte Inc | 38.5 | ||
| Xenon Pharmaceuticals Inc | 37.2 | ||
| MIND Medicine Mindmed Inc | 32.9 | ||
| LB Pharmaceuticals Inc | 32.5 | ||
| Mirum Pharmaceuticals Inc | 30.8 | ||
| Nurix Therapeutics Inc | 27.0 | ||
| Revolution Medicines Inc | 23.8 | ||
| Arcus Biosciences Inc | 22.6 | ||
| Immunocore Holdings PLC | 20.6 | ||
| Cytokinetics Inc | 19.8 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold ($M) | AUM ($M) |
|---|---|---|---|---|
| HF | Trails Edge Biotechnology Master Fund LP | [2025-10-06] | 0.0 | 933.4 |
| Filed 2025-06-25 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 933.4 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 933.4 |
| By Discretionary | ||
| Discretionary | 3 | 933.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 933.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 385.3 | |
| United States Persons | 548.1 | |
| Total | 3 | 933.4 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Trails Edge Capital Partners LP | Executive Officer | 2 | 2 | |
| Trails Edge Biotechnology Fund GP LP | Executive Officer | 2 | 2 | |
| Ortav Yehudai | Executive Officer | 2 | 2 | |
| Matthew Diaz | Executive Officer | 2 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0002077247] | |
| SC 13G | [0002077247] |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
Converium Capital Inc
✚
|
1.0 | |
|
Ground Swell Capital LLC
✚
|
SC | 0.9 |
|
DGV Solutions LP
✚
|
MN | 0.9 |
|
Taproot Management LP
✚
|
NY | 0.9 |
|
MAC Alpha Capital Management LP
✚
|
FL | 0.9 |
|
Sirios Capital Management LP
✚
|
MA | 0.9 |
|
Brilliance Asset Management Limited
✚
|
0.9 | |
|
NW1 Partners UK LLP
✚
|
0.9 | |
|
Clearalpha Technologies LP
✚
|
CT | 0.9 |
|
MIRI Capital Management LLC
✚
|
MA | 0.9 |